ATE554392T1 - Diagnoseverfahren für sprue/zöliakie - Google Patents

Diagnoseverfahren für sprue/zöliakie

Info

Publication number
ATE554392T1
ATE554392T1 AT03789958T AT03789958T ATE554392T1 AT E554392 T1 ATE554392 T1 AT E554392T1 AT 03789958 T AT03789958 T AT 03789958T AT 03789958 T AT03789958 T AT 03789958T AT E554392 T1 ATE554392 T1 AT E554392T1
Authority
AT
Austria
Prior art keywords
sprue
celiac disease
diagnostic procedure
digestion
refractory
Prior art date
Application number
AT03789958T
Other languages
English (en)
Inventor
Chaitan Khosla
Lu Shan
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE554392T1 publication Critical patent/ATE554392T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03789958T 2002-11-20 2003-11-20 Diagnoseverfahren für sprue/zöliakie ATE554392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42803302P 2002-11-20 2002-11-20
PCT/US2003/037434 WO2004045392A2 (en) 2002-11-20 2003-11-20 Diagnostic method for celiac sprue

Publications (1)

Publication Number Publication Date
ATE554392T1 true ATE554392T1 (de) 2012-05-15

Family

ID=32326628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789958T ATE554392T1 (de) 2002-11-20 2003-11-20 Diagnoseverfahren für sprue/zöliakie

Country Status (8)

Country Link
US (3) US7776545B2 (de)
EP (1) EP1563300B1 (de)
AT (1) ATE554392T1 (de)
AU (1) AU2003294473A1 (de)
CA (1) CA2502700C (de)
DK (1) DK1563300T3 (de)
ES (1) ES2383595T3 (de)
WO (1) WO2004045392A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
DK1572127T4 (da) * 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
CA2487247A1 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
ATE554392T1 (de) 2002-11-20 2012-05-15 Univ Leland Stanford Junior Diagnoseverfahren für sprue/zöliakie
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US10105437B2 (en) * 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
CN104056251B (zh) * 2004-04-28 2019-09-17 英国技术集团国际有限公司 与腹部疾病有关的表位
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
CN103933563B (zh) 2007-01-25 2016-09-28 英特瑞克斯顿阿克图比奥帝克斯有限公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
CA2680590C (en) * 2007-03-16 2017-10-17 Jonathan David Gass Combination enzyme therapy for digestion of dietary gluten
US8148105B2 (en) * 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
ES2421719T3 (es) * 2008-04-21 2013-09-05 Bio Rad Laboratories Antígeno de gliadina recombinante desamidada
CN105079781B (zh) 2008-11-30 2018-07-20 免疫桑特公司 用于治疗乳糜泻的组合物和方法
HU0900195D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis and treatment of gluten-induced autoimmune diseases
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
WO2011000773A1 (en) * 2009-07-02 2011-01-06 Dsm Ip Assets B.V. Testing efficacy for celiac disease
DE102009045268A1 (de) * 2009-10-01 2011-04-07 Charité - Universitätsmedizin Berlin Neue Marker für die Diagnose von Zöliakie
US8685392B2 (en) 2009-10-07 2014-04-01 Trustees Of Boston University Rothia species glutamine endopeptidases and use thereof
CN102858795A (zh) 2010-02-02 2013-01-02 天野酶制品美国有限公司 蛋白酶针对谷蛋白不耐受的用途
WO2012006384A2 (en) 2010-07-07 2012-01-12 Trustees Of Boston University Rothia species gluten-degrading enzymes and uses thereof
ES2385455B2 (es) * 2010-12-28 2013-09-25 Universidad De Sevilla Determinación de niveles de péptidos inmunogénicos del gluten en muestras humanas.
ES2896489T3 (es) 2011-08-10 2022-02-24 Univ Washington Through Its Center For Commercialization Composiciones y procedimientos para el tratamiento de la enfermedad esprúe celíaco
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
WO2013085851A2 (en) * 2011-12-05 2013-06-13 Bio-Rad Laboratories, Inc. Recombinant deamidated gliadin antigen
EP3033100B1 (de) 2013-08-14 2018-10-03 University Of Washington Through Its Center For Commercialization Zusammensetzungen zur behandlung von zöliakie
EP3043812A1 (de) 2013-09-10 2016-07-20 Immusant Inc. Dosierung einer glutenpeptidzusammensetzung
AU2015249383A1 (en) * 2014-04-24 2016-12-15 Immusant, Inc. Compositions comprising gluten peptides and uses thereof
ES2556177B1 (es) * 2014-07-09 2016-10-20 Universidad De Sevilla Detección de péptidos del gluten en fluidos humanos
US10370718B2 (en) 2014-09-29 2019-08-06 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease
SG10201911867YA (en) 2015-06-08 2020-01-30 Univ Washington Compositions and methods for treating celiac sprue disease

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2451388A1 (de) 1973-10-31 1975-05-07 James Joseph Phelan Verfahren zur entgiftung von kleber in nahrungsmitteln
US4203967A (en) 1977-01-13 1980-05-20 Hoffmann-La Roche Inc. Diagnostic test for malabsorption
US4562003A (en) * 1984-10-26 1985-12-31 California Biotechnology, Inc. Monoclonal antibodies against alveolar surfactant protein
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
US4929630A (en) 1986-03-14 1990-05-29 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
KR900006545B1 (ko) 1986-03-14 1990-09-13 신텍스(미합중국) 인코포레이티드 트란스글루타미나제 억제제
DD262999A1 (de) 1987-07-27 1988-12-21 Adw Ddr Verfahren zur herstellung eines diaetetikums fuer zoeliakie- und spruekranke
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
GB9225021D0 (en) 1992-11-30 1993-01-20 Sandoz Ltd Organic compounds
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
US6197356B1 (en) 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
AU1739395A (en) * 1994-02-07 1995-08-21 United States Of America, As Represented By The Secretary Of Agriculture, The Detection of wheat that has experienced elevated temperatures during the grain filling period
JPH10508005A (ja) 1994-09-29 1998-08-04 メルク エンド カンパニー インコーポレーテッド チオールを有しないファルネシル−タンパク質トランスフェラーゼ阻害剤
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
GB9509336D0 (en) 1995-05-09 1995-06-28 Dynal As Chemical method
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20020018763A1 (en) 1995-05-24 2002-02-14 Kriszkina M. Zsebo A method of stimulating growth of stromal cells with stem cell factor (scf) polypeptides
DE19630557C2 (de) 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
EP0821238B1 (de) 1996-07-24 2003-07-02 Antonio Picarelli Verfahren und Testsatz zur in vitro Bestätigung der Diagnose von Bauchkrankheit
US5912327A (en) 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6635462B1 (en) 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
EP0905518A1 (de) 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptiden spezifisch für Glutenempfindliche T-Zellen und Verwendung davon
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
ME00459B (me) 1997-12-31 2011-10-10 Pfizer Prod Inc Aril fuzirana azapoliciklična jedinjenja
WO1999056698A2 (en) * 1998-05-06 1999-11-11 Københavns Universitet Treatment of celiac disease
US6201695B1 (en) * 1998-10-26 2001-03-13 Micron Technology, Inc. Heat sink for chip stacking applications
WO2000033077A1 (en) * 1998-12-04 2000-06-08 Barnes-Jewish Hospital Cell matrix plaques of initial bone formation
WO2000042213A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
GB9912350D0 (en) 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6962989B1 (en) * 1999-07-08 2005-11-08 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding novel proteins
US6395889B1 (en) * 1999-09-09 2002-05-28 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human protease homologs
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
AU7878900A (en) 1999-10-15 2001-04-30 Heska Corporation Method for production and use of mite group 1 proteins
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US6667160B2 (en) * 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US6642036B2 (en) 2000-07-07 2003-11-04 E. I. Du Pont De Nemours And Company Sinapoylglucose:malate sinapoyltransferase form malate conjugates from benozic acid glucosides
US6833447B1 (en) * 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
EP1201136A1 (de) * 2000-10-31 2002-05-02 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Transglutaminasehemmer mit Nahrungsmittelqualitität und Verwendungen davon
EP1464234A1 (de) 2000-12-07 2004-10-06 DSM IP Assets B.V. Verfahren zur Verhinderung oder Verminderung der Trübung in Getränken
CN100506981C (zh) 2000-12-07 2009-07-01 Dsmip资产有限公司 富含具有羧基末端脯氨酸残基的肽的蛋白质水解产物
WO2002057296A1 (en) 2001-01-16 2002-07-25 Københavns Universitet A method for refolding of proteins
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20040241161A1 (en) 2001-04-12 2004-12-02 Drijfhout Jan Wouter Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
US6645739B2 (en) 2001-07-26 2003-11-11 Phoenix Pharmacologies, Inc. Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
NO20015814D0 (no) * 2001-11-28 2001-11-28 Amersham Health As Metallkompleksforbindelser
EP1332760A1 (de) * 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Neue Epitope für Zöliakie und Autoimmunerkrankungen, Methoden zu deren Detektion und neue nichtantigene Futterzusätze
DK1572127T4 (da) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US20030224476A1 (en) * 2002-03-01 2003-12-04 Szu-Yi Chou Method of producing transglutaminase reactive compound
CA2487247A1 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
US7265093B2 (en) 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US6903246B2 (en) * 2002-05-28 2005-06-07 The Regents Of The University Of California Dehydroascorbate reductase (“DHAR”) genes from Triticum aestivum and their use to modulate ascorbic acid levels in plants
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
ATE554392T1 (de) 2002-11-20 2012-05-15 Univ Leland Stanford Junior Diagnoseverfahren für sprue/zöliakie
CN1311076C (zh) 2003-04-16 2007-04-18 普罗特奥姆技术公司 生产重组尿激酶的方法
US20050049064A1 (en) * 2003-09-02 2005-03-03 Gagne Robert M. Golf training apparatus
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US20050227920A1 (en) 2003-12-11 2005-10-13 Xinli Lin Methods for production of recombinant vascular endothelial cell growth inhibitor
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7521427B2 (en) 2004-11-09 2009-04-21 Georgia Tech Research Corporation Peptidyl allyl sulfones
EP1949093A2 (de) 2005-10-11 2008-07-30 Alvine Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur verbesserten stabilität von oligopeptiden und polypeptiden im magen-darm-trakt
WO2007047303A2 (en) * 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
WO2007050795A2 (en) * 2005-10-25 2007-05-03 Alvine Pharmaceuticals, Inc. Transglutaminase inhibitors and methods of use thereof
US20070099238A1 (en) 2005-10-31 2007-05-03 Sigalas Mihail M Enhancement of emission using metal coated dielectric nanoparticles
EP1845103B1 (de) 2006-04-10 2015-02-25 Boehringer Ingelheim RCV GmbH & Co KG Verfahren zur Proteinfaltung
US8148105B2 (en) 2007-03-16 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Scaleable manufacturing process for cysteine endoprotease B, isoform 2
CA2680590C (en) 2007-03-16 2017-10-17 Jonathan David Gass Combination enzyme therapy for digestion of dietary gluten
ES2616231T3 (es) 2008-08-21 2017-06-12 Immunogenics Llc Formulación para administración oral de proteínas
NZ591940A (en) 2008-10-10 2013-08-30 Alvine Pharmaceuticals Inc Dosage forms that facilitate rapid activation of zymogen

Also Published As

Publication number Publication date
US7776545B2 (en) 2010-08-17
ES2383595T3 (es) 2012-06-22
US8071316B2 (en) 2011-12-06
WO2004045392A3 (en) 2004-08-26
WO2004045392A2 (en) 2004-06-03
US20100317025A1 (en) 2010-12-16
EP1563300A2 (de) 2005-08-17
DK1563300T3 (da) 2012-07-23
US20120083004A1 (en) 2012-04-05
AU2003294473A8 (en) 2004-06-15
US20060240475A1 (en) 2006-10-26
EP1563300B1 (de) 2012-04-18
CA2502700C (en) 2017-01-17
CA2502700A1 (en) 2004-06-03
AU2003294473A1 (en) 2004-06-15
EP1563300A4 (de) 2010-08-11
US8426145B2 (en) 2013-04-23

Similar Documents

Publication Publication Date Title
ATE554392T1 (de) Diagnoseverfahren für sprue/zöliakie
WO2007019411A3 (en) Peptides for diagnostic and therapeutic methods for celiac sprue
ATE470391T1 (de) System für die probenahme und analyse in vivo
ATE457830T1 (de) Probensubstrat zur biologischen untersuchung
MX374971B (es) Metodos y aparato para la deteccion de sensibilidad al gluten y su diferenciacion de la enfermedad celiaca
TW200512457A (en) Method of diagnosing SARS corona virus infection
WO2008089072A3 (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
BRPI0618713B8 (pt) cardiolipina modificada e seus usos
EP3546939A3 (de) Test zur messung von zellvermittelter immunansprechbarkeit
WO2007002579A3 (en) Assay cartridges and methods for point of care instruments
HUP0203691A2 (hu) Nemhagyományos transzmisszibilis ágens biológiai mintabeli jelenlétének kimutatásán alapuló eljárás szubakut transzmisszibilis spongiform encephalopathia diagnózisára
WO2006024466A3 (de) Testvorrichtung für die in vitro diagnostik von multianalyt-tests und deren verwendung
ATE514081T1 (de) T-zellen-testverfahren
NO20051024L (no) Fremgangsmate for diagnostisering av multippel sklerose
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
ATE271225T1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
BRPI0712629C1 (pt) método para a detecção da apoptose e método para a identificação de uma célula de câncer humano
CA2407760A1 (en) Methods for diagnosis of low grade astrocytoma
WO2003081206A3 (en) Stratification of patient populations having or suspected of having rheumatoid arthritis
EP1774327A4 (de) Verfahren und kits zur messung von adamts13/fxi-komplexen
ATE412180T1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
WO2007000169A3 (en) Non-human mammalian arthritis model featuring human antibodies against citrullinated proteins
FI990380A7 (fi) Diagnostinen ja seulontamenetelmä
EP1636587A4 (de) Einen für menschliches protoonkogenes protein spezifischen antikörper enthaltender diagnostischer kit für leberzirrhose